Takeda Pharmaceuticals Co Ltd on Monday announced the expansion of its rare disease portfolio in India with the launch of Adynovate for the treatment of haemophilia.

Adynovate is an innovative half-life-extending recombinant factor VIII (rFVIII) treatment using proven technology to treat patients with haemophilia A. The company said it provided an effective bleeding solution with virtually zero spontaneous bleeding in most cases, improved joint health, and reduced infusion frequency and associated pain.

Haemophilia A is a rare inherited bleeding disorder caused by mutations in the gene encoding the blood clotting protein factor VIII. “The launch of Adynovate is another step in addressing the haemophilia treatment gap and helping healthcare professionals and patients better manage the condition. We hope this new treatment will help redefine what is possible for haemophilia patients in India,” said Serina Fischer, Managing Director of Takeda India.

• The 5 index signals smart traders watch before placing a single order
• Kwality Pharma Hits 52-Week High After Record FY26 Revenue
• Jay Bharat Maruti Hits 20% Upper Circuit on 287% Profit Surge
• ZEEL Falls 6% After Q4 Swings to Net Loss on Ad Revenue Miss
• Overnight Stock Market Movements: Key Developments 

Takeda said its Adynovate, combined with the FDA-approved app MYPKFIT, offers personalised and interactive preventive treatment options, enabling healthcare professionals (HCPs) and patients to monitor factor VIII levels in real-time smartphones and adjust activity accordingly to make decisions and help improve their quality of life.
It added that prophylactic treatment alerts are sent to patients when their estimated factor VIII levels are low and remind them when their infusions are due, providing excellent preventive coverage.